Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation

被引:1
|
作者
Zhang, Ran [1 ]
Lu, Xuan [2 ]
Tang, Liang V. [2 ]
Wang, Huafang [2 ]
Yan, Han [2 ]
You, Yong [2 ]
Zhong, Zhaodong [2 ]
Shi, Wei [2 ]
Xia, Linghui [2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
haploidentical hematopoietic stem cell transplantation; graft composition; G-CSF-mobilized BM cells; G-CSF-mobilized PBSCs; total nucleated cells; MOBILIZED PERIPHERAL-BLOOD; PRIMED BONE-MARROW; POSTTRANSPLANT CYCLOPHOSPHAMIDE; CONDITIONING REGIMEN; LEUKEMIA; OUTCOMES; SURVIVAL;
D O I
10.3389/fimmu.2022.993419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05x10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20x10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies
    Rundgren, Ida Marie
    Ersvaer, Elisabeth
    Ahmed, Aymen Bushra
    Ryningen, Anita
    Bruserud, Oystein
    MEDICINA-LITHUANIA, 2020, 56 (01):
  • [22] Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis
    Yang, Xue
    Li, Dongjun
    Xie, Yao
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] Late Toxicity in Children Undergoing Hematopoietic Stem Cell Transplantation with TBI-containing Conditioning Regimens for Hematological Malignancies
    Ricardi, Umberto
    Filippi, Andrea Riccardo
    Biasin, Eleonora
    Ciammella, Patrizia
    Botticella, Angela
    Franco, Pierfrancesco
    Corrias, Andrea
    Vassallo, Elena
    Ragona, Riccardo
    Fagioli, Franca
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 17 - 20
  • [24] Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
    Shimoni, Avichai
    Nagler, Arnon
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1395 - 1396
  • [25] Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies
    Saengboon, Supawee
    Ciurea, Stefan
    Popat, Uday
    Ramdial, Jeremy
    Bashir, Qaiser
    Alousi, Amin
    Chen, Julianne
    Rondon, Gabriela
    Olson, Amanda
    Im, Jin
    Hosing, Chitra
    Shpall, Elizabeth
    Champlin, Richard
    Srour, Samer A.
    BLOOD ADVANCES, 2024, 8 (12) : 3237 - 3245
  • [26] A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies
    Nakamae, Hirohisa
    Okamura, Hiroshi
    Hirose, Asao
    Koh, Hideo
    Nakashima, Yasuhiro
    Nakamae, Mika
    Nishimoto, Mitsutaka
    Makuuchi, Yosuke
    Kuno, Masatomo
    Harada, Naonori
    Takakuwa, Teruhito
    Hino, Masayuki
    CELL TRANSPLANTATION, 2022, 31
  • [27] Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia
    Nagler, Arnon
    Dholaria, Bhagirathbhai
    Labopin, Myriam
    Savani, Bipin N.
    Angelucci, Emanuele
    Koch, Yener
    Arat, Mutlu
    Pioltelli, Pietro
    Sica, Simona
    Gulbas, Zafer
    Tischer, Johanna
    Bernasconi, Paolo
    Pavlu, Jiri
    Socie, Gerard
    Blaise, Didier
    Rigacci, Luigi
    Martino, Massimo
    Diez-Martin, Jose Luis
    Peric, Zinaida
    Giebel, Sebastian
    Mohty, Mohamad
    LEUKEMIA, 2020, 34 (10) : 2766 - 2775
  • [28] High Incidence of Early Human Herpesvirus-6 Infection in Children Undergoing Haploidentical Manipulated Stem Cell Transplantation for Hematologic Malignancies
    Perruccio, Katia
    Sisinni, Luisa
    Perez-Martinez, Antonio
    Valentin, Jaime
    Capolsini, Ilaria
    Massei, Maria Speranza
    Caniglia, Maurizio
    Cesaro, Simone
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (12) : 2549 - 2557
  • [29] The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age
    Dong, Lujia
    Wu, Tong
    Gao, Zhi-Yong
    Zhang, Mei-Jie
    Kan, Fangyu
    Spellman, Stephen R.
    Tan, Xi-You
    Zhao, Yan-Li
    Wang, Jing-Bo
    Lu, Dao-Pei
    Miklos, David
    Petersdorf, Effie
    Fernandez-Vina, Marcelo
    Lee, Stephanie J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (08) : 1205 - 1213
  • [30] Coping in patients with hematologic malignancies undergoing hematopoietic cell transplantation
    Newcomb, Richard
    Amonoo, Hermioni L.
    Nelson, Ashley M.
    Choe, Joanna
    Holmbeck, Katherine
    Nabily, Anisa
    Lee, Stephanie J.
    Leblanc, Thomas W.
    El-Jawahri, Areej
    BLOOD ADVANCES, 2024, 8 (06) : 1369 - 1378